Inhibition of TNFa-induced activation of nuclear factor ¿B by kava (Piper methysticum) derivatives

Florence Jacqueline Folmer, R. Blasius, F. Morceau, Jioji Natadra Tabudravu, M. Dicato, Marcel Jaspars, M. Diedrich

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

The inducible transcription factor nuclear factor kappa B (NF-kappa B) plays a central role in the regulation of immune, inflammatory and carcinogenic responses. While normal activation of NF-kappa B is required for cell survival and immunity, its deregulated expression is a characteristic of inflammatory and infectious diseases. In this study, we investigated the molecular mechanisms induced by lactones and chalcones isolated from Fijian kava (Piper methysticum) used in traditional medicine against urinary tract infections and asthma. In order to understand underlying regulatory mechanisms, inhibition of both NF-kappa B-driven reporter gene expression and TNF alpha-induced binding of NF-kappa B to a consensus response element was achieved at concentrations of 320 mu M (flavokavain A), 175 mu M (flavokavain B) and 870 mu M (kavain and dihydrokavain). Moreover, kavain and flavokavains A and B treatment led to inhibition of both inhibitor of kappa B (I kappa B) degradation and subsequent translocation of p50 and p65 NF-kappa B subunits from the cytoplasm to the nucleus as shown by Western blot analysis. Additionally, kinase selectivity screening demonstrates that flavokavain A, but not kavain, nor flavokavain B, inhibits the I kappa B kinase (IKK) as well as PRAK (p38-regulated/activated kinase), MAPKAP-K3 (MAPK-activated protein kinase 3), DYRK1A (dual-specificity tyrosine-phosporylated and regulated kinase 1A) and Aurora B. Altogether, these results give a first insight into anti-inflammatory mechanisms triggered by traditionally used chemopreventive kava compounds. (c) 2006 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)1206-1218
Number of pages12
JournalBiochemical Pharmacology
Volume71
Issue number71
DOIs
Publication statusPublished - 2006

Keywords

  • chalcones
  • ethnopharmacology
  • kava
  • lactones
  • NF-kappa B
  • TNF alpha
  • K562
  • ANTITUMORIGENIC ACTIVITIES
  • CYCLOOXYGENASE ENZYME
  • CHALCONE DERIVATIVES
  • DRUG DEVELOPMENT
  • GENE-EXPRESSION
  • CELLS
  • KAVALACTONES
  • PROTEIN
  • CANCER
  • GROWTH

Cite this

Inhibition of TNFa-induced activation of nuclear factor ¿B by kava (Piper methysticum) derivatives. / Folmer, Florence Jacqueline; Blasius, R.; Morceau, F.; Tabudravu, Jioji Natadra; Dicato, M.; Jaspars, Marcel; Diedrich, M.

In: Biochemical Pharmacology, Vol. 71, No. 71, 2006, p. 1206-1218.

Research output: Contribution to journalArticle

Folmer, Florence Jacqueline ; Blasius, R. ; Morceau, F. ; Tabudravu, Jioji Natadra ; Dicato, M. ; Jaspars, Marcel ; Diedrich, M. / Inhibition of TNFa-induced activation of nuclear factor ¿B by kava (Piper methysticum) derivatives. In: Biochemical Pharmacology. 2006 ; Vol. 71, No. 71. pp. 1206-1218.
@article{c5e25a4fd21c445eabe13ea3c8a9403c,
title = "Inhibition of TNFa-induced activation of nuclear factor ¿B by kava (Piper methysticum) derivatives",
abstract = "The inducible transcription factor nuclear factor kappa B (NF-kappa B) plays a central role in the regulation of immune, inflammatory and carcinogenic responses. While normal activation of NF-kappa B is required for cell survival and immunity, its deregulated expression is a characteristic of inflammatory and infectious diseases. In this study, we investigated the molecular mechanisms induced by lactones and chalcones isolated from Fijian kava (Piper methysticum) used in traditional medicine against urinary tract infections and asthma. In order to understand underlying regulatory mechanisms, inhibition of both NF-kappa B-driven reporter gene expression and TNF alpha-induced binding of NF-kappa B to a consensus response element was achieved at concentrations of 320 mu M (flavokavain A), 175 mu M (flavokavain B) and 870 mu M (kavain and dihydrokavain). Moreover, kavain and flavokavains A and B treatment led to inhibition of both inhibitor of kappa B (I kappa B) degradation and subsequent translocation of p50 and p65 NF-kappa B subunits from the cytoplasm to the nucleus as shown by Western blot analysis. Additionally, kinase selectivity screening demonstrates that flavokavain A, but not kavain, nor flavokavain B, inhibits the I kappa B kinase (IKK) as well as PRAK (p38-regulated/activated kinase), MAPKAP-K3 (MAPK-activated protein kinase 3), DYRK1A (dual-specificity tyrosine-phosporylated and regulated kinase 1A) and Aurora B. Altogether, these results give a first insight into anti-inflammatory mechanisms triggered by traditionally used chemopreventive kava compounds. (c) 2006 Elsevier Inc. All rights reserved.",
keywords = "chalcones, ethnopharmacology, kava, lactones, NF-kappa B, TNF alpha, K562, ANTITUMORIGENIC ACTIVITIES, CYCLOOXYGENASE ENZYME, CHALCONE DERIVATIVES, DRUG DEVELOPMENT, GENE-EXPRESSION, CELLS, KAVALACTONES, PROTEIN, CANCER, GROWTH",
author = "Folmer, {Florence Jacqueline} and R. Blasius and F. Morceau and Tabudravu, {Jioji Natadra} and M. Dicato and Marcel Jaspars and M. Diedrich",
year = "2006",
doi = "10.1016/j.bcp.2005.12.032",
language = "English",
volume = "71",
pages = "1206--1218",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "71",

}

TY - JOUR

T1 - Inhibition of TNFa-induced activation of nuclear factor ¿B by kava (Piper methysticum) derivatives

AU - Folmer, Florence Jacqueline

AU - Blasius, R.

AU - Morceau, F.

AU - Tabudravu, Jioji Natadra

AU - Dicato, M.

AU - Jaspars, Marcel

AU - Diedrich, M.

PY - 2006

Y1 - 2006

N2 - The inducible transcription factor nuclear factor kappa B (NF-kappa B) plays a central role in the regulation of immune, inflammatory and carcinogenic responses. While normal activation of NF-kappa B is required for cell survival and immunity, its deregulated expression is a characteristic of inflammatory and infectious diseases. In this study, we investigated the molecular mechanisms induced by lactones and chalcones isolated from Fijian kava (Piper methysticum) used in traditional medicine against urinary tract infections and asthma. In order to understand underlying regulatory mechanisms, inhibition of both NF-kappa B-driven reporter gene expression and TNF alpha-induced binding of NF-kappa B to a consensus response element was achieved at concentrations of 320 mu M (flavokavain A), 175 mu M (flavokavain B) and 870 mu M (kavain and dihydrokavain). Moreover, kavain and flavokavains A and B treatment led to inhibition of both inhibitor of kappa B (I kappa B) degradation and subsequent translocation of p50 and p65 NF-kappa B subunits from the cytoplasm to the nucleus as shown by Western blot analysis. Additionally, kinase selectivity screening demonstrates that flavokavain A, but not kavain, nor flavokavain B, inhibits the I kappa B kinase (IKK) as well as PRAK (p38-regulated/activated kinase), MAPKAP-K3 (MAPK-activated protein kinase 3), DYRK1A (dual-specificity tyrosine-phosporylated and regulated kinase 1A) and Aurora B. Altogether, these results give a first insight into anti-inflammatory mechanisms triggered by traditionally used chemopreventive kava compounds. (c) 2006 Elsevier Inc. All rights reserved.

AB - The inducible transcription factor nuclear factor kappa B (NF-kappa B) plays a central role in the regulation of immune, inflammatory and carcinogenic responses. While normal activation of NF-kappa B is required for cell survival and immunity, its deregulated expression is a characteristic of inflammatory and infectious diseases. In this study, we investigated the molecular mechanisms induced by lactones and chalcones isolated from Fijian kava (Piper methysticum) used in traditional medicine against urinary tract infections and asthma. In order to understand underlying regulatory mechanisms, inhibition of both NF-kappa B-driven reporter gene expression and TNF alpha-induced binding of NF-kappa B to a consensus response element was achieved at concentrations of 320 mu M (flavokavain A), 175 mu M (flavokavain B) and 870 mu M (kavain and dihydrokavain). Moreover, kavain and flavokavains A and B treatment led to inhibition of both inhibitor of kappa B (I kappa B) degradation and subsequent translocation of p50 and p65 NF-kappa B subunits from the cytoplasm to the nucleus as shown by Western blot analysis. Additionally, kinase selectivity screening demonstrates that flavokavain A, but not kavain, nor flavokavain B, inhibits the I kappa B kinase (IKK) as well as PRAK (p38-regulated/activated kinase), MAPKAP-K3 (MAPK-activated protein kinase 3), DYRK1A (dual-specificity tyrosine-phosporylated and regulated kinase 1A) and Aurora B. Altogether, these results give a first insight into anti-inflammatory mechanisms triggered by traditionally used chemopreventive kava compounds. (c) 2006 Elsevier Inc. All rights reserved.

KW - chalcones

KW - ethnopharmacology

KW - kava

KW - lactones

KW - NF-kappa B

KW - TNF alpha

KW - K562

KW - ANTITUMORIGENIC ACTIVITIES

KW - CYCLOOXYGENASE ENZYME

KW - CHALCONE DERIVATIVES

KW - DRUG DEVELOPMENT

KW - GENE-EXPRESSION

KW - CELLS

KW - KAVALACTONES

KW - PROTEIN

KW - CANCER

KW - GROWTH

U2 - 10.1016/j.bcp.2005.12.032

DO - 10.1016/j.bcp.2005.12.032

M3 - Article

VL - 71

SP - 1206

EP - 1218

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 71

ER -